In Ohio, the Cleveland Clinic joined the Circulating Cell-free Genome Atlas, a national clinical trial that is looking for 7,000 cancer patients and 3,000 healthy patients in the U.S. Their goal is to analyze DNA and RNA in the blood and build a database that will help with detecting cancer early on when it is easier to cure. Researchers believe that using genome sequencing from blood samples could possibly replace x-rays for early cancer detection. Funded by a company in California, GRAIL, Inc., the project will be looking for molecule patterns in the blood for specific types of cancers.
Latest article
Ajinomoto combines two biotech ingredients in futuristic latte
In Singapore, iced lattes made from beanless coffee and cow-free proteins pulled from air will be available shortly in a preview at the country’s...
San Fran hotspot Fiorella hosts Mission Barns’ first cultivated pork sale
In California, cultivated meat maker Mission Barns has sold its pork for the first time at an exclusive dinner at San Francisco hot spot...
Uluu raises $10.4M to scale seaweed-based plastic
In Australia, seaweed-based plastic startup Uluu has raised AU$16 million (US$10.4 million) to build a demonstration plant to prove the viability of its technology.
Uluu’s...